Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient

Autor: Lars Fugger, Ralf Gold, Kate Attfield, Astrid K. N. Iversen, Hannah Wurm, Aiden Haghikia
Jazyk: angličtina
Rok vydání: 2020
Předmět:
medicine.medical_treatment
CD4-CD8 Ratio
Coronavirus Infections/complications
Case Report and Clinical Commentary
Gastroenterology
Immunoglobulin G
rituximab
0302 clinical medicine
0303 health sciences
biology
B-Lymphocytes/immunology
Middle Aged
medicine.anatomical_structure
Neurology
Killer Cells
Natural/immunology
CD4-Positive T-Lymphocytes/immunology
Disease Progression
Rituximab
Female
Antibody
medicine.drug
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
B-cell-depleting therapy
Multiple Sclerosis
Chronic Progressive/complications
cellular immune responses
03 medical and health sciences
Betacoronavirus
Internal medicine
Rituximab/therapeutic use
medicine
Humans
Lymphocyte Count
Pandemics
B cell
030304 developmental biology
SARS-CoV-2 antibodies
business.industry
Multiple sclerosis
COVID-19
Immunotherapy
medicine.disease
Multiple sclerosis (MS)
Immunity
Cellular/immunology
biology.protein
Neurology (clinical)
Pneumonia
Viral/complications
business
030217 neurology & neurosurgery
Zdroj: Attfield, K, Iversen, A K, Gold, R, Fugger, L & Haghikia, A 2020, ' Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient ', Multiple sclerosis (Houndmills, Basingstoke, England), vol. 26, no. 10, pp. 1261-1264 . https://doi.org/10.1177/1352458520943791
Multiple Sclerosis (Houndmills, Basingstoke, England)
Popis: Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examined 5 days before the onset of coronavirus disease 2019 (COVID-19) symptoms and was admitted to the hospital 2 days after. She recovered 14 days after symptom onset despite having a 0% B lymphocyte count and not developing SARS-CoV-2 immunoglobulin G (IgG) antibodies.
Databáze: OpenAIRE
Externí odkaz: